

Characterization of Dual PTEN and p53-Targeting MicroRNAs Identifies MicroRNA-638/Dnm2 as a Two-Hit Oncogenic Locus

Yvonne Tay,¹ Shen Mynn Tan,^{2,3} Florian A. Karreth,^{1,4} Judy Lieberman,^{2,3} and Pier Paolo Pandolfi^{1,*}

¹Cancer Research Institute, Beth Israel Deaconess Cancer Center, Department of Medicine and Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA

²Cellular and Molecular Medicine Program, Boston Children's Hospital, Boston, MA 02115, USA

³Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA

⁴Present address: Meyer Cancer Center, Weill Cornell Medical College, New York, NY 10021, USA

*Correspondence: ppandolf@bidmc.harvard.edu

<http://dx.doi.org/10.1016/j.celrep.2014.06.064>

This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/3.0/>).

SUMMARY

Tumor suppressor genes (TSGs) are often concomitantly lost or mutated in human cancers and have been shown to act synergistically to promote tumorigenesis. In addition to genomic alterations, posttranscriptional regulation by microRNAs (miRNAs) represents another mechanism by which TSG expression is dysregulated in cancers. Although miRNAs that target critical TSGs such as *PTEN* or *p53* have been identified, little is known about miRNAs that concomitantly regulate both these key TSGs. In this study, we characterize microRNA 518c* (miR-518c*) and miR-638 as dual *PTEN*- and *p53*-targeting miRNAs that are upregulated in multiple human cancers. We focus on miR-638 and show that it associates independently with these two tumor suppressor transcripts as well as *BRCA1*, a known miR-638 target. We find that miR-638 overexpression promotes tumorigenesis and demonstrate cooperativity between miR-638 and its host gene *Dnm2*, suggesting that the *Dnm2* locus encodes two distinct oncogenic components that play important roles in tumorigenesis.

INTRODUCTION

PTEN (phosphatase and tensin homolog deleted on chromosome 10) is one of the most frequently lost and mutated tumor suppressor genes (TSGs) in a wide spectrum of human cancers. *PTEN* encodes a plasma membrane lipid phosphatase that functions predominantly as an inhibitor of the proto-oncogenic phosphatidylinositol 3-kinase-AKT signaling pathway that regulates cell growth and survival (Song et al., 2012). In vivo models that demonstrate that heterozygous *PTEN* loss and an even subtler reduction in its expression leads to

an increased incidence of spontaneous tumors in multiple tissue types provide further support for the key tumor-suppressive function of *PTEN* (Berger et al., 2011; Di Cristofano et al., 1998).

p53, epitomized as the “guardian of the genome,” is one of the most-studied and frequently mutated or deleted TSGs. It encodes a transcription factor that regulates the expression of target genes involved in DNA repair, cell-cycle arrest, apoptosis, senescence, and other cellular processes (Vousden and Lane, 2007). Additional evidence for the importance of *p53* in tumorigenesis was provided by mouse models that demonstrated that either the heterozygous or homozygous loss of *p53* leads to an increased risk for cancer in a variety of tissues (Donehower et al., 1992).

The functions of these two TSGs are intricately intertwined. *PTEN* has been shown to physically associate with *p53*, regulate its DNA-binding activity, and protect it from Mdm2-mediated degradation (Freeman et al., 2003; Mayo et al., 2002). Conversely, *p53* has been reported to regulate *PTEN* transcription (Stambolic et al., 2001). Several studies have examined the functional relevance of this reciprocal cooperation between *PTEN* and *p53*. Chen et al. found that although *Pten* inactivation leads to nonlethal invasive cancer in the prostate after long latency and *p53* inactivation did not lead to cancer, combined *Pten* and *p53* inactivation resulted in invasive prostate cancer in mice with lethality by 7 months (Chen et al., 2005). Puzio-Kuter et al. observed that *Pten* or *p53* single-mutant mice did not develop bladder tumors up to 1 year of age, but inactivation of both genes led to large tumors with 100% penetrance by 6 months (Puzio-Kuter et al., 2009). Andjelkovic et al. found that the loss of both these genes occurred frequently in patients with non-small-cell lung cancer, was associated with increased lymph node invasion, and reduced survival (Andjelkovic et al., 2011).

Collectively, these reports suggest that these two TSGs may crosstalk at multiple levels and that their compound inactivation is an event that is strongly selected for in human cancers. This in turn led us to hypothesize that mechanisms that induce the concomitant downregulation of both these tumor suppressors may play key roles in cancer development. Aside

from genetic deletions or mutations that result in the heterozygous or homozygous loss of *PTEN* or *p53* function, other mechanisms that contribute to the dysregulation of *PTEN* or *p53* expression in cancers include epigenetic silencing, transcriptional repression, posttranslational modifications, and posttranscriptional regulation by microRNAs (miRNAs) (Song et al., 2012).

miRNAs are small noncoding RNAs that modulate gene expression by binding to specific recognition sites on target transcripts (Bartel and Chen, 2004). Several studies have identified miRNAs that target either the *PTEN* or *p53* transcripts (Hermeking, 2012; Tay et al., 2013). However, little is known about miRNAs that concomitantly regulate both these key TSGs. In this study, we characterize miR-518c* and miR-638 as dual *PTEN* and *p53*-targeting miRNAs. We find that overexpression of miR-638, which is encoded in the oncogenic *Dnm2* locus, promotes tumorigenic properties, including cell proliferation, migration, and invasion. These data suggest that the *Dnm2* gene comprises a two-hit oncogenic locus that plays an important role in cancer progression.

RESULTS

Identification of Potential Dual *PTEN* and *p53*-Targeting miRNAs

We first performed miRNA target-prediction analyses to identify miRNAs that may target both full-length *PTEN* and *p53* transcripts (Table S1). Because the combined loss of *PTEN* and *p53* has been shown to promote prostate cancer metastasis (Abou-Kheir et al., 2011), we next examined the expression profiles of these miRNAs in prostate cancer. Of the 51 predicted dual-targeting miRNAs, 14 were upregulated in human metastatic prostate cancer samples (Figures 1A and S1A). We selected miR-518c*, miR-584, and miR-638 for experimental validation because their expression levels were also increased in colon and kidney cancers (Figures S1B and S1C), additional cancers with frequent loss of *PTEN* and *p53*.

Next, we investigated their effect on endogenous *PTEN* and *p53* levels. Overexpression of miR-518c*, miR-584, and miR-638 resulted in a significant decrease in *PTEN* protein levels in both HCT116 colon cancer and U2OS osteosarcoma cell lines that express wild-type *PTEN* and *p53* (Figures 1B and 1C). This was accompanied by a concomitant increase in Akt activation. Similarly, miR-518c*, miR-584, and miR-638 reduced *p53* protein levels and decreased expression of p21, a downstream effector of *p53* (Figures 1D and 1E).

Direct Regulation of the *PTEN* and *p53* Transcripts by miR-518c* and miR-638

Because *PTEN* and *p53* have been shown to reciprocally coregulate each other as discussed above, we next investigated whether these observed effects were due to bona fide miRNA targeting or were alternatively a result of protein-mediated crosstalk. PC3 prostate cancer cells were selected as an ideal model system for this purpose because they are *PTEN*

null and *p53* null and do not express detectable levels of either transcript or protein (Isaacs et al., 1991; Vlietstra et al., 1998).

miR-518c*, miR-584, and miR-638 have predicted target sites in the 5' UTR and/or coding region of *PTEN* and *p53* (Figure S2A). To examine whether these predictions represented functional binding sites, we first constructed vectors expressing the 5' UTR plus coding region of *PTEN* and *p53* and cotransfected them into PC3 cells with miR-518c*, miR-584, or miR-638. Overexpression of miR-518c* and miR-638 significantly downregulated the expression of both 5' UTR plus coding sequence (CDS) constructs, suggesting that their effect on *PTEN* and *p53* is partly 3' UTR independent (Figures 2A and 2B). Although miR-584 also downregulated expression of exogenous *PTEN*, it did not have a significant effect on exogenous *p53* expression. This suggests that the predicted miR-584 microRNA response elements (MREs) in *p53* are not bona fide MREs and that miR-584's effect on endogenous *p53* is most likely indirect.

Next, we generated luciferase reporter constructs harboring the various fragments (5' UTR, CDS [–ATG], and 3' UTR) of the *PTEN* and *p53* transcripts. Overexpression of miR-638 resulted in a modest but significant decrease in expression of the *PTEN*-5' UTR, CDS (–ATG), and 3' UTR reporters, as well as the *p53*-CDS (–ATG) and 3' UTR reporters (Figures 2C and 2D). It did not affect the *p53*-5' UTR reporter. These results are consistent with the location of predicted MREs on these transcripts.

miR-518c* overexpression reduced expression of the *PTEN*-CDS (–ATG) and *p53*-5' UTR constructs, consistent with the location of several predicted MREs (Figures 2C and 2D). However, it did not affect expression of the *PTEN*-5' UTR or *p53*-CDS (–ATG) reporters, suggesting that these predictions were not bona fide MREs. Furthermore, it significantly reduced expression of the *PTEN*-3' UTR reporter, suggesting the existence of additional MREs.

miR-584 overexpression reduced expression of the *PTEN*-5' UTR and *PTEN*-CDS (–ATG) constructs, consistent with the location of its predicted *PTEN* MREs (Figure 2C). Its ability to reduce expression of the *PTEN*-3' UTR reporter suggests that it may also have additional target sites there. Consistent with our earlier observations, it did not have a significant effect on any of the *p53* reporters. Taken together, these data provide evidence that *PTEN* is a bona fide target of miR-584 and suggest that both miR-638 and miR-518c* are dual *PTEN* and *p53*-targeting miRNAs.

miR-638 Independently Targets *PTEN*, *p53*, and *BRCA1*

Intriguingly, *BRCA1* has been identified as a target of miR-638 (Nicoloso et al., 2010). *BRCA1* is an important TSG involved in DNA damage repair and the maintenance of genomic stability, and the *BRCA1* protein has been shown to reciprocally coregulate *p53* and Akt signaling (Altiok et al., 1999; Zhang et al., 1998). To disentangle potential miRNA-mediated regulation from protein-dependent crosstalk, we performed biotinylated miRNA pull-downs to examine the direct association of miR-638 with each of these tumor suppressor transcripts. We found that *PTEN*, *p53*, and *BRCA1* transcripts were enriched in miR-638




Figure 1. Identification of Potential Dual PTEN and p53-Targeting miRNAs

(A) Expression of miR-584, miR-638, and miR-518c* in primary and metastatic prostate cancer compared to normal prostate.

(B and C) Effect of miR-584, miR-638, or miR-518c* overexpression on endogenous PTEN and P-Akt expression. Representative western blots are shown in (B), and quantitation of all blots is shown in (C).

(D and E) Effect of miR-584, miR-638, or miR-518c* overexpression on endogenous p53 and p21 expression. Representative western blots are shown in (D), and quantitation of all blots is shown in (E).

(C and E) Mean \pm SD. (A, C, and E) * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$. See also [Figure S1](#) and [Table S1](#).




Figure 2. miR-638 and miR-518c* Directly Target PTEN and p53

(A) Expression of exogenous PTEN and P-Akt in PC3 cells after cotransfection of the negative control (NC), miR-518c*, miR-584, or miR-638 with a plasmid construct expressing only the PTEN 5' UTR plus CDS.

(B) Expression of exogenous p53 and p21 in PC3 cells after cotransfection of the NC, miR-518c*, miR-584, or miR-638 with a plasmid construct expressing only the p53 5' UTR plus CDS.

(C and D) Luciferase validation assays demonstrating the effect of miR-518c*, miR-584, or miR-638 overexpression on the 5' UTR, 3' UTR, and ATG-less CDS fragments of (C) PTEN and (D) p53 relative to the NC in PC3 cells.

(E) Expression of PTEN, p53, and BRCA1 mRNAs in biotinylated miR-638 pull-downs from U2OS cells.

Mean \pm SD; $n \geq 4$. * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$. See also Figure S2.

pression of miR-638 resulted in a modest but significant reduction in the levels of all these reporter constructs (Figure S2B), except for the PTEN-C2 MRE, which appeared to have a cell-type-dependent effect.

Although miRNA binding to MREs in the coding regions and 3' UTRs of target genes generally results in the repression of gene expression, miRNA binding to 5' UTRs may enhance translation (Ørom et al., 2008). To investigate the potential context-dependent effect of the miR-638 5' UTR and CDS MREs, we generated reporter constructs with the 5' UTR MREs upstream of the luciferase reporter and the CDS MREs just upstream and in frame with the luciferase stop codon. Overexpression of miR-638 resulted in a modest but significant reduction in the levels of these PTEN 5'1, 5'3, C1, and p53 C1 MRE reporter constructs in PC3 cells (Figure S2C). These data are consistent with our previous observations when they were cloned into the luciferase 3' UTR and suggest that these MREs do not function in a context-dependent manner. However, we no longer saw a significant reduction in luciferase activity with the PTEN 5'2 MRE cloned into the

pull-downs, suggesting that they all independently associate with miR-638 (Figure 2E).

miR-638 was shown to regulate *BRCA1* by binding to a single MRE in its coding region. To identify the specific MREs responsible for its regulation of *PTEN* and *p53*, we cloned the predicted miR-638 MREs downstream of a luciferase reporter. Overex-

pression of miR-638 resulted in a modest but significant reduction in the levels of these PTEN 5'1, 5'3, C1, and p53 C1 MRE reporter constructs in PC3 cells (Figure S2C). These data are consistent with our previous observations when they were cloned into the luciferase 3' UTR and suggest that these MREs do not function in a context-dependent manner. However, we no longer saw a significant reduction in luciferase activity with the PTEN 5'2 MRE cloned into the

luciferase 5' UTR or the PTEN C2 MRE cloned into the luciferase-coding region, suggesting that these two MREs may not be functional in their endogenous contexts.

We next performed site-directed mutagenesis of the seed regions of the CDS and 3' UTR MREs in the luciferase reporter constructs harboring the corresponding full-length transcript




Figure 3. Overexpression of miR-638 and miR-518c* Promotes Tumorigenesis

Effect of miR-638 or miR-518c* overexpression on cell migration (A) and invasion (B), proliferation (C), and anchorage-independent growth (D) in vitro. Mean \pm SD; $n \geq 4$. ** $p < 0.01$; *** $p < 0.001$. See also Figure S3.

for the functional relevance of the upregulation of these miRNAs in various pathophysiological conditions.

We subsequently focused our attention on miR-638 due to its ability to target *PTEN*, *p53*, and *BRCA1*, and because it had a consistently stronger effect on enhancing tumorigenic potential in vitro. Notably, we found that miR-638 overexpression increased the growth of colon cancer xenograft tumors in nude mice (Figure S3G). Next, we determined endogenous miR-638 expression levels in a panel of cell lines with wild-type *PTEN*, *p53*, and *BRCA1* (Figure S4A). All cell lines tested expressed detectable levels of miR-638, with the highest levels observed in U2OS and HCT116 cells. Inhibition of endogenous miR-638 resulted in a significant upregulation of *PTEN* and *p53* protein levels (Figure 4E), with a concomitant decrease in cell proliferation, migration, and invasion (Figures 4F and 4G). These data are complementary

to those observed in the overexpression experiments and provide further evidence for the functional role of physiological levels of miR-638 in regulating *PTEN* and *p53* levels.

fragments. Mutation of the *PTEN* C1 and *p53* 3'1 MREs resulted in complete rescue of the miR-638-mediated suppression of the respective luciferase constructs, whereas mutation of the *PTEN* 3'1 and *p53* C1 MREs resulted in a partial but significant rescue of the respective luciferase constructs (Figure S2D). These results provide further support for the functional role of these MREs in miR-638-mediated *PTEN* and *p53* regulation.

Overexpression of miR-638 and miR-518c* Promotes Tumorigenesis

PTEN and *p53* have been shown to function as important regulators of cell migration, invasion, and proliferation. We thus hypothesized that miR-518c* and miR-638 may be critical modulators of these hallmarks of tumorigenesis. In vitro wound healing and Boyden chamber assays demonstrated that overexpression of miR-518c* or miR-638 resulted in a significant increase in both cell migration (Figures 3A, S3A, and S3B) and invasion (Figures 3B and S3C). Additionally, miR-518c* or miR-638 overexpression increased cell proliferation (Figure 3C) and enhanced anchorage-independent growth in soft agar (Figures 3D, S3D, and S3E). Similar effects on target gene expression, cell proliferation, and migration were observed with 2 nM of transfected mimic (Figures 4A–4D). Because this amount of transfected mimic is more representative of the fold induction observed in cancers (Figure S3F), these data provide support

to those observed in the overexpression experiments and provide further evidence for the functional role of physiological levels of miR-638 in regulating *PTEN* and *p53* levels.

miR-638 Is a Functionally Relevant Component of the Oncogenic DNM2 Locus

The miR-638 precursor is located in the first intron of the *DNM2* gene (Figure 5A). *DNM2* is a microtubule-associated, GTP-binding protein, and recent reports have demonstrated that its overexpression promotes growth, migration, and invasion in various cancers (Eppinga et al., 2012; Feng et al., 2012). On this basis, we hypothesized that the *DNM2* locus may represent a two-hit oncogenic locus that produces both the *DNM2* protein and miR-638.

To test this hypothesis, we first overexpressed miR-638 and *DNM2* independently and in combination in both HCT116 and U2OS cells. As previously reported, *DNM2* overexpression led to an increase in cell proliferation (Figure 5B) (Feng et al., 2012). The concurrent overexpression of both miR-638 and *DNM2* significantly augmented cell growth above that observed with either miR-638 or *DNM2* alone (Figure 5B). Next, we investigated potential cooperativity between miR-638 knockdown and *DNM2* inhibition. U2OS cells were selected for proof of principle studies because they expressed the highest levels of endogenous miR-638. Growth curve analyses




Figure 4. Functional Relevance of Physiological Levels of miR-638 and miR-518c*

(A and B) Effect of miR-518c* or miR-638 overexpression (transfected at 2 nM) on endogenous PTEN and p53 expression. Representative western blots are shown in (A) and quantitation of all blots is shown in (B).

(C and D) Effect of miR-518c* or miR-638 overexpression (transfected at 2 nM) on cell proliferation (C) and migration (D).

(E) Effect of miR-638 inhibition (638AS) on endogenous PTEN and p53 expression. Representative western blots are shown in the top panel, and quantitation of all blots is shown below.

(F and G) Effect of miR-638 inhibition on cell proliferation (F), migration (G, top panel), and invasion (G, bottom panel).

Mean \pm SD; n \geq 4. *p < 0.05; **p < 0.01; ***p < 0.001.

demonstrated that the combined effect of miR-638 knockdown and either Dynasore or MiTMAB, two small molecule inhibitors of DNM function, led to a reduction in cell proliferation that was

significantly greater than that observed with miR-638 knockdown or Dynasore or MiTMAB treatment alone (Figure 5C). These data suggest that miR-638 and the DNM2 protein




Figure 5. miR-638 Is Part of the Oncogenic DNMT2 Locus

(A) Schematic depicting the location of the miR-638 precursor in the DNMT2 gene.

(B) Effect of the combinatorial overexpression of miR-638 and Dnm2 on cell proliferation.

(C) Combined effect of miR-638 knockdown and the Dynamin inhibitors Dynasore (Dyna; left panel) and MiTMAB (right panel) on cell proliferation in U2OS cells.

Mean \pm SD; $n \geq 4$. * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$. See also Figure S4.

represent two distinct oncogenic components encoded by the DNMT2 locus.

DISCUSSION

In this study, we examine miRNA-mediated posttranscriptional regulation of the full-length *PTEN* and *p53* transcripts and their role in promoting tumorigenesis. We characterize miR-518c* and miR-638 as *PTEN* and *p53*-targeting miRNAs and confirm previous reports that identify *BRCA1* as an additional miR-638 target (Li et al., 2012; Nicoloso et al., 2010). These miRNAs may represent a powerful mechanism to simultaneously modulate levels of these key TSGs that are known to cooperate reciprocally to inhibit tumorigenesis.

Existing studies have focused exclusively on the 3' UTRs of *PTEN* and *p53* as sites for miRNA regulation. It has been shown in both cancer cell lines and primary tumors that transcripts often have shorter 3' UTRs in cancer cells compared to untransformed cells and thus may be subject to less 3' UTR-dependent miRNA regulation (Lembo et al., 2012; Mayr and Bartel, 2009). For example, *PTEN*, *p53*, and *BRCA1* have three (Lianoglou et al., 2013), three, and seven validated alternative polyadenylation sites, respectively. It is thus conceivable that the ability of miR-638 and miR-518c* to bind and regulate these transcripts in a partly 3' UTR-independent fashion may enable them to modulate the expression of a larger subset of transcript variants. This may be of particular relevance in cancer cells with reduced 3' UTR-dependent miRNA regulation. Interestingly, the miR-638-binding site in *BRCA1* identified by Nicoloso et al. (2010) was in its coding region.

The role of these miRNAs in tumorigenesis remains largely uncharacterized. miR-518c* is located in the chromosome 19 miRNA

cluster (C19MC), which is the largest human miRNA gene cluster discovered to date (Bortolin-Cavaillé et al., 2009). This miRNA cluster has been reported to be amplified in aggressive embryonal brain and parathyroid tumors and epigenetically reactivated through DNA demethylation in gastric cancer (Li et al., 2009; Tsai et al., 2009; Vaira et al., 2012). Specifically, elevated levels of miR-518c* were reported to be significantly associated with reduced progression-free survival in bladder carcinoma (Dyrskjot et al., 2009).

The miR-638 precursor is located in the first intron of the Dnm2 gene. Our data suggest that the Dnm2 locus encodes two distinct proto-oncogenic components that play important roles in tumorigenesis. Copy number amplifications at this locus were observed in ovarian and uterine cancers (Figure S4B). In accordance with this, DNMT2 transcript expression was found to be significantly elevated in multiple ovarian cancer data sets (Figure S4C). Critically, miR-638 amplification was found to be significantly associated with decreased patient survival in ovarian cancer (Figure S4D). Additional studies reported that high expression levels of miR-638 were significantly associated with shorter overall survival in adrenocortical carcinoma (Özata et al., 2011) and squamous cell lung carcinoma (Landi et al., 2010). These data provide further support for the functional relevance of miR-638 in human cancers.

Interestingly, it has been reported that miR-638 is one of several miRNAs that is selectively packaged in membrane vesicles released from cancer cells (Jaiswal et al., 2012). A very recent study found that miR-638 was one of only three serum miRNAs inversely associated with overall survival in patients with nasopharyngeal carcinoma (Liu et al., 2014). Aside from its function in a cell of origin, miR-638 may be able to regulate gene expression in recipient cells and thus play an important role in the intercellular regulation of cancer development.

Related work from our group and others has demonstrated that transcripts that contain binding sites for shared miRNAs can coregulate each other by titrating miRNA availability, thus functioning as natural miRNA sponges or competing endogenous RNAs (ceRNAs) (Tay et al., 2014). In particular, much effort has focused on characterization of the PTEN ceRNA network. Our study suggests that in certain conditions whereby the

abundance of *PTEN*, *p53*, and *BRCA1* falls within the range for optimal ceRNA crosstalk, their ability to sequester miR-518c* and miR-638 may represent an additional mechanism of reciprocal coregulation between these TSGs. Furthermore, existing studies that examine ceRNA crosstalk between protein-coding transcripts have been limited exclusively to 3' UTR-dependent regulation. We suggest that expanding ceRNA crosstalk analysis to include 5' UTRs and coding regions of protein-coding transcripts may lead to new insights into this network of competitive miRNA-RNA interactions and to the identification of novel TSGs or oncogenes based on their ceRNA function.

EXPERIMENTAL PROCEDURES

miRNA target prediction was performed using Rna22 (Miranda et al., 2006). MREs and transcript fragments were cloned into pscheck2 and pcDNA3.1 according to standard protocols. For the pscheck2 constructs, the 5' UTR fragments were cloned upstream of the luciferase-coding region, whereas the CDS and 3' UTR fragments were cloned in the luciferase 3' UTR. Site-directed mutagenesis was performed according to the manufacturer's protocols using the QuikChange Lightning Site-Directed Mutagenesis Kit from Agilent Technologies. HCT116, U2OS, and PC3 cells were cultured under standard conditions. miRNA mimics and inhibitors were purchased from Dharmacon. Transient transfections were performed with 2 or 100 nM of miRNA mimic or inhibitor with DharmaFECT 1 according to the manufacturer's protocols. Western blot, real-time PCR, and luciferase assays were performed as previously described (Tay et al., 2008). Biotinylated miRNA pull-downs were performed as previously described by Lal et al. (2011). Growth curves and soft agar assays were performed as previously described (Tay et al., 2011). Wound healing, transwell migration, and xenograft assays were performed according to standard protocols. All mouse work was performed in accordance with our IACUC protocol. Invasion assays were performed using Matrigel Invasion Chambers from BD Biosciences according to the manufacturer's protocols.

SUPPLEMENTAL INFORMATION

Supplemental Information includes Supplemental Experimental Procedures, four figures, and one table and can be found with this article online at <http://dx.doi.org/10.1016/j.celrep.2014.06.064>.

ACKNOWLEDGMENTS

We thank P.P.P. laboratory members for critical discussions and Ivano Legnini and Francesca Orso for technical assistance. Y.T. was supported by a Special Fellow Award from The Leukemia & Lymphoma Society. S.M.T. was supported by a Department of Defense Breast Cancer Research Program postdoctoral fellowship award. F.A.K. was supported by a Department of Defense Prostate Cancer Research Program fellowship award. This work was supported in part by NIH grant R01 CA-82328 (to P.P.P.).

Received: March 5, 2014

Revised: May 30, 2014

Accepted: June 30, 2014

Published: July 31, 2014

REFERENCES

- Abou-Kheir, W., Hynes, P.G., Martin, P., Yin, J.J., Liu, Y.N., Seng, V., Lake, R., Spurrier, J., and Kelly, K. (2011). Self-renewing Pten-/- TP53-/- protospheres produce metastatic adenocarcinoma cell lines with multipotent progenitor activity. *PLoS One* 6, e26112.
- Altioik, S., Batt, D., Altioik, N., Papautsky, A., Downward, J., Roberts, T.M., and Avraham, H. (1999). Heregulin induces phosphorylation of BRCA1 through phosphatidylinositol 3-Kinase/AKT in breast cancer cells. *J. Biol. Chem.* 274, 32274–32278.
- Andjelkovic, T., Bankovic, J., Stojic, J., Milinkovic, V., Podolski-Renic, A., Ruzdijic, S., and Tanic, N. (2011). Coalterations of p53 and PTEN tumor suppressor genes in non-small cell lung carcinoma patients. *Transl. Res.* 157, 19–28.
- Bartel, D.P., and Chen, C.Z. (2004). Micromanagers of gene expression: the potentially widespread influence of metazoan microRNAs. *Nat. Rev. Genet.* 5, 396–400.
- Berger, A.H., Knudson, A.G., and Pandolfi, P.P. (2011). A continuum model for tumour suppression. *Nature* 476, 163–169.
- Bortolin-Cavaillé, M.L., Dance, M., Weber, M., and Cavaillé, J. (2009). C19MC microRNAs are processed from introns of large Pol-II, non-protein-coding transcripts. *Nucleic Acids Res.* 37, 3464–3473.
- Chen, Z., Trotman, L.C., Shaffer, D., Lin, H.K., Dotan, Z.A., Niki, M., Koutcher, J.A., Scher, H.I., Ludwig, T., Gerald, W., et al. (2005). Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. *Nature* 436, 725–730.
- Di Cristofano, A., Pesce, B., Cordon-Cardo, C., and Pandolfi, P.P. (1998). Pten is essential for embryonic development and tumour suppression. *Nat. Genet.* 19, 348–355.
- Donehower, L.A., Harvey, M., Slagle, B.L., McArthur, M.J., Montgomery, C.A., Jr., Butel, J.S., and Bradley, A. (1992). Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. *Nature* 356, 215–221.
- Dyrskjot, L., Ostenfeld, M.S., Bramsen, J.B., Silahtaroglu, A.N., Lamy, P., Ramanathan, R., Fristrup, N., Jensen, J.L., Andersen, C.L., Zieger, K., et al. (2009). Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. *Cancer Res.* 69, 4851–4860.
- Eppinga, R.D., Krueger, E.W., Weller, S.G., Zhang, L., Cao, H., and McNiven, M.A. (2012). Increased expression of the large GTPase dynamin 2 potentiates metastatic migration and invasion of pancreatic ductal carcinoma. *Oncogene* 31, 1228–1241.
- Feng, H., Liu, K.W., Guo, P., Zhang, P., Cheng, T., McNiven, M.A., Johnson, G.R., Hu, B., and Cheng, S.Y. (2012). Dynamin 2 mediates PDGFR α -SHP-2-promoted glioblastoma growth and invasion. *Oncogene* 31, 2691–2702.
- Freeman, D.J., Li, A.G., Wei, G., Li, H.H., Kertesz, N., Lesche, R., Whale, A.D., Martinez-Diaz, H., Rozengurt, N., Cardiff, R.D., et al. (2003). PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. *Cancer Cell* 3, 117–130.
- Hermeking, H. (2012). MicroRNAs in the p53 network: micromanagement of tumour suppression. *Nat. Rev. Cancer* 12, 613–626.
- Isaacs, W.B., Carter, B.S., and Ewing, C.M. (1991). Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. *Cancer Res.* 51, 4716–4720.
- Jaiswal, R., Luk, F., Gong, J., Mathys, J.M., Grau, G.E., and Bebawy, M. (2012). Microparticle conferred microRNA profiles—implications in the transfer and dominance of cancer traits. *Mol. Cancer* 11, 37.
- Lal, A., Thomas, M.P., Altschuler, G., Navarro, F., O'Day, E., Li, X.L., Conception, C., Han, Y.C., Thiery, J., Rajani, D.K., et al. (2011). Capture of microRNA-bound mRNAs identifies the tumor suppressor miR-34a as a regulator of growth factor signaling. *PLoS Genet.* 7, e1002363.
- Landi, M.T., Zhao, Y., Rotunno, M., Koshiol, J., Liu, H., Bergen, A.W., Rubagotti, M., Goldstein, A.M., Linnoila, I., Marincola, F.M., et al. (2010). MicroRNA expression differentiates histology and predicts survival of lung cancer. *Clin. Cancer Res.* 16, 430–441.
- Lembo, A., Di Cunto, F., and Provero, P. (2012). Shortening of 3'UTRs correlates with poor prognosis in breast and lung cancer. *PLoS One* 7, e31129.
- Li, M., Lee, K.F., Lu, Y., Clarke, I., Shih, D., Eberhart, C., Collins, V.P., Van Meter, T., Picard, D., Zhou, L., et al. (2009). Frequent amplification of a chr19q13.41 microRNA polycistron in aggressive primitive neuroectodermal brain tumors. *Cancer Cell* 16, 533–546.
- Li, D., Wang, Q., Liu, C., Duan, H., Zeng, X., Zhang, B., Li, X., Zhao, J., Tang, S., Li, Z., et al. (2012). Aberrant expression of miR-638 contributes to benzo(a)pyrene-induced human cell transformation. *Toxicol. Sci.* 125, 382–391.

- Lianoglou, S., Garg, V., Yang, J.L., Leslie, C.S., and Mayr, C. (2013). Ubiquitously transcribed genes use alternative polyadenylation to achieve tissue-specific expression. *Genes Dev.* *27*, 2380–2396.
- Liu, N., Cui, R.X., Sun, Y., Guo, R., Mao, Y.P., Tang, L.L., Jiang, W., Liu, X., Cheng, Y.K., He, Q.M., et al. (2014). A four-miRNA signature identified from genome-wide serum miRNA profiling predicts survival in patients with nasopharyngeal carcinoma. *Int. J. Cancer* *134*, 1359–1368.
- Mayo, L.D., Dixon, J.E., Durden, D.L., Tonks, N.K., and Donner, D.B. (2002). PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy. *J. Biol. Chem.* *277*, 5484–5489.
- Mayr, C., and Bartel, D.P. (2009). Widespread shortening of 3'UTRs by alternative cleavage and polyadenylation activates oncogenes in cancer cells. *Cell* *138*, 673–684.
- Miranda, K.C., Huynh, T., Tay, Y., Ang, Y.S., Tam, W.L., Thomson, A.M., Lim, B., and Rigoutsos, I. (2006). A pattern-based method for the identification of MicroRNA binding sites and their corresponding heteroduplexes. *Cell* *126*, 1203–1217.
- Nicoloso, M.S., Sun, H., Spizzo, R., Kim, H., Wickramasinghe, P., Shimizu, M., Wojcik, S.E., Ferdin, J., Kunej, T., Xiao, L., et al. (2010). Single-nucleotide polymorphisms inside microRNA target sites influence tumor susceptibility. *Cancer Res.* *70*, 2789–2798.
- Ørom, U.A., Nielsen, F.C., and Lund, A.H. (2008). MicroRNA-10a binds the 5'UTR of ribosomal protein mRNAs and enhances their translation. *Mol. Cell* *30*, 460–471.
- Özata, D.M., Caramuta, S., Velázquez-Fernández, D., Akçakaya, P., Xie, H., Höög, A., Zedenius, J., Bäckdahl, M., Larsson, C., and Lui, W.O. (2011). The role of microRNA deregulation in the pathogenesis of adrenocortical carcinoma. *Endocr. Relat. Cancer* *18*, 643–655.
- Puzio-Kuter, A.M., Castillo-Martin, M., Kinkade, C.W., Wang, X., Shen, T.H., Matos, T., Shen, M.M., Cordon-Cardo, C., and Abate-Shen, C. (2009). Inactivation of p53 and Pten promotes invasive bladder cancer. *Genes Dev.* *23*, 675–680.
- Song, M.S., Salmena, L., and Pandolfi, P.P. (2012). The functions and regulation of the PTEN tumour suppressor. *Nat. Rev. Mol. Cell Biol.* *13*, 283–296.
- Stambolic, V., MacPherson, D., Sas, D., Lin, Y., Snow, B., Jang, Y., Benchimol, S., and Mak, T.W. (2001). Regulation of PTEN transcription by p53. *Mol. Cell* *8*, 317–325.
- Tay, Y., Zhang, J., Thomson, A.M., Lim, B., and Rigoutsos, I. (2008). MicroRNAs to Nanog, Oct4 and Sox2 coding regions modulate embryonic stem cell differentiation. *Nature* *455*, 1124–1128.
- Tay, Y., Kats, L., Salmena, L., Weiss, D., Tan, S.M., Ala, U., Karreth, F., Poliseno, L., Provero, P., Di Cunto, F., et al. (2011). Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs. *Cell* *147*, 344–357.
- Tay, Y., Song, S.J., and Pandolfi, P.P. (2013). The Lilliputians and the giant: an emerging oncogenic miRNA network that suppresses the PTEN tumor suppressor in vivo. *MicroRNA* *2*, 127–136.
- Tay, Y., Rinn, J., and Pandolfi, P.P. (2014). The multilayered complexity of ceRNA crosstalk and competition. *Nature* *505*, 344–352.
- Tsai, K.W., Kao, H.W., Chen, H.C., Chen, S.J., and Lin, W.C. (2009). Epigenetic control of the expression of a primate-specific microRNA cluster in human cancer cells. *Epigenetics* *4*, 587–592.
- Vaira, V., Elli, F., Forno, I., Guarnieri, V., Verdelli, C., Ferrero, S., Scillitani, A., Vicentini, L., Cetani, F., Mantovani, G., et al. (2012). The microRNA cluster C19MC is deregulated in parathyroid tumours. *J. Mol. Endocrinol.* *49*, 115–124.
- Vlietstra, R.J., van Alewijk, D.C., Hermans, K.G., van Steenbrugge, G.J., and Trapman, J. (1998). Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. *Cancer Res.* *58*, 2720–2723.
- Vousden, K.H., and Lane, D.P. (2007). p53 in health and disease. *Nat. Rev. Mol. Cell Biol.* *8*, 275–283.
- Zhang, H., Somasundaram, K., Peng, Y., Tian, H., Zhang, H., Bi, D., Weber, B.L., and El-Deiry, W.S. (1998). BRCA1 physically associates with p53 and stimulates its transcriptional activity. *Oncogene* *16*, 1713–1721.